United Capital Financial Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.18M | Buy |
12,438
+212
| +2% | +$94K | 0.03% | 333 |
|
|
2026
Q1 | $5.46M | Buy |
12,226
+149
| +1% | +$69.5K | 0.03% | 350 |
|
|
2025
Q4 | $5.48M | Buy |
12,077
+565
| +5% | +$244K | 0.03% | 341 |
|
|
2025
Q3 | $4.51M | Sell |
11,512
-1,610
| -12% | -$673K | 0.03% | 322 |
|
|
2025
Q2 | $5.84M | Buy |
13,122
+1,156
| +10% | +$533K | 0.05% | 259 |
|
|
2025
Q1 | $5.8M | Buy |
11,966
+602
| +5% | +$281K | 0.05% | 253 |
|
|
2024
Q4 | $4.58M | Sell |
11,364
-21
| -0.2% | -$9.73K | 0.04% | 271 |
|
|
2024
Q3 | $5.29M | Buy |
11,385
+1,013
| +10% | +$487K | 0.04% | 253 |
|
|
2024
Q2 | $4.86M | Buy |
10,372
+151
| +1% | +$65.5K | 0.04% | 265 |
|
|
2024
Q1 | $4.27M | Buy |
10,221
+199
| +2% | +$84.1K | 0.04% | 305 |
|
|
2023
Q4 | $4.08M | Buy |
10,022
+1,437
| +17% | +$531K | 0.03% | 314 |
|
|
2023
Q3 | $2.99M | Sell |
8,585
-185
| -2% | -$64.7K | 0.02% | 371 |
|
|
2023
Q2 | $3.09M | Sell |
8,770
-152
| -2% | -$51.2K | 0.02% | 380 |
|
|
2023
Q1 | $2.81M | Sell |
8,922
-998
| -10% | -$299K | 0.02% | 397 |
|
|
2022
Q4 | $2.86M | Sell |
9,920
-211
| -2% | -$64.3K | 0.02% | 416 |
|
|
2022
Q3 | $2.93M | Buy |
10,131
+5,446
| +116% | +$1.57M | 0.02% | 411 |
|
|
2022
Q2 | $1.32M | Buy |
4,685
+3,439
| +276% | +$920K | 0.01% | 579 |
|
|
2022
Q1 | $325K | Sell |
1,246
-256
| -17% | -$60.8K | ﹤0.01% | 965 |
|
|
2021
Q4 | $330K | Buy |
1,502
+48
| +3% | +$9.33K | ﹤0.01% | 1000 |
|
|
2021
Q3 | $264K | Sell |
1,454
-570
| -28% | -$111K | ﹤0.01% | 1055 |
|
|
2021
Q2 | $408K | Sell |
2,024
-371
| -15% | -$77.6K | ﹤0.01% | 925 |
|
|
2021
Q1 | $515K | Sell |
2,395
-640
| -21% | -$141K | ﹤0.01% | 841 |
|
|
2020
Q4 | $717K | Sell |
3,035
-21,264
| -88% | -$4.88M | ﹤0.01% | 759 |
|
|
2020
Q3 | $6.61M | Sell |
24,299
-98
| -0.4% | -$27K | 0.04% | 294 |
|
|
2020
Q2 | $7.08M | Buy |
24,397
+3,846
| +19% | +$1.04M | 0.05% | 302 |
|
|
2020
Q1 | $4.89M | Sell |
20,551
-2,853
| -12% | -$654K | 0.04% | 345 |
|
|
2019
Q4 | $5.12M | Buy |
23,404
+384
| +2% | +$77.7K | 0.03% | 416 |
|
|
2019
Q3 | $3.9M | Buy |
23,020
+795
| +4% | +$141K | 0.03% | 468 |
|
|
2019
Q2 | $4.08M | Buy |
22,225
+2,653
| +14% | +$464K | 0.03% | 458 |
|
|
2019
Q1 | $3.6M | Buy |
19,572
+2,435
| +14% | +$450K | 0.03% | 470 |
|
|
2018
Q4 | $2.84M | Buy |
17,137
+2,449
| +17% | +$424K | 0.02% | 484 |
|
|
2018
Q3 | $2.83M | Buy |
14,688
+2,949
| +25% | +$525K | 0.02% | 540 |
|
|
2018
Q2 | $2M | Buy |
11,739
+2,495
| +27% | +$387K | 0.01% | 593 |
|
|
2018
Q1 | $1.51M | Sell |
9,244
-3,586
| -28% | -$586K | 0.01% | 660 |
|
|
2017
Q4 | $1.92M | Buy |
12,830
+1,101
| +9% | +$163K | 0.02% | 598 |
|
|
2017
Q3 | $1.78M | Buy |
11,729
+6,633
| +130% | +$998K | 0.02% | 612 |
|
|
2017
Q2 | $657K | Buy |
+5,096
| New | +$613K | 0.01% | 866 |
|
Other funds holding VRTX
United Capital Financial Advisors's VRTX Position: Q2 2026 in Review
United Capital Financial Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 1.7% in Q2 2026, buying an estimated $94K and bringing the position to 12,438 shares worth $6.18M. The position accounts for 0.03% of the portfolio, ranked #333.
United Capital Financial Advisors first reported a position in VRTX in Q2 2017 and has held it in 37 quarters since. The position peaked at $7.08M in Q2 2020. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- United Capital Financial Advisors held 12,438 shares of Vertex Pharmaceuticals worth $6.18M as of Q2 2026.
- United Capital Financial Advisors bought 212 Vertex Pharmaceuticals shares in Q2 2026, an estimated $94K.
- Vertex Pharmaceuticals made up 0.03% of United Capital Financial Advisors's portfolio in Q2 2026, its #333 holding.
- United Capital Financial Advisors first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 37 quarters since.
- United Capital Financial Advisors's Vertex Pharmaceuticals position peaked at $7.08M in Q2 2020.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on United Capital Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.